| Literature DB >> 35173726 |
Diya Tang1,2, Shanshan Liu1,2, Hong Shen2, Gongping Deng3, Shan Zeng1.
Abstract
Globally, gastric cancer (GC) ranks fourth in the incidence of malignant tumors. The early clinical manifestations of GC lack specificity. Most patients are already at an advanced stage when they are first diagnosed, and their late progression is mainly due to peritoneal metastasis. A pre-metastatic microenvironment is formed, before the macroscopic tumor metastasis. Extracellular vesicles (EVs) are nanovesicles released by cells into body fluids. Recent studies have shown that EVs can affect the tumor microenvironment by carrying cargos to participate in cell-to-cell communication. EVs derived from GC cells mediate the regulation of the pre-metastasis niche and act as a coordinator between tumor cells and normal stroma, immune cells, inflammatory cells, and tumor fibroblasts to promote tumor growth and metastasis. This review highlights the regulatory role of EVs in the pre-metastatic niche of GC and mulls EVs as a potential biomarker for liquid biopsy.Entities:
Keywords: extracellular vesicles; gastric cancer; immunomodulation; microenvironment; pre-metastatic
Mesh:
Substances:
Year: 2022 PMID: 35173726 PMCID: PMC8841609 DOI: 10.3389/fimmu.2022.813015
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1The biogenesis of EVs and the mechanism of the formation of pre-metastasis microenvironment. The biogenesis of EVs includes the occurrence of exosomes and microvesicles. By acting as communicators between donor and recipient cells, EVs induce immunomodulation, angiogenesis, stromal remodeling, and barrier disruption, ultimately contributing to the pre-metastasis microenvironment.
Summary of proteins in EVs involved in GC progression and metastasis.
| Extracellular vesicles proteins | Recipient cells/Target | Role/Mechanism |
|---|---|---|
| CD97 | NA | Lymphatic metastasis ( |
| CD97 | MAPK signaling pathway | Proliferation and Invasion ( |
| FZD10 | NA | Carcinogenesis and Tumor proliferation ( |
| FZD10 | Wnt signaling pathway | Cancer progression ( |
| MET | TAMs | Cancer progression ( |
| TGF-β1 | Treg cells | Lymphatic metastasis ( |
| EGFR | HGF | Liver metastasis ( |
Evs, Extracellular vesicles; EGFR, Epidermal growth factor receptor; FZD10, Frizzled10; GC, Gastric cancer; HGF, Hepatocyte growth factor; TAMs, Tumor-associated macrophages; Treg, Regulatory T; TGF-β1, Transforming growth factor β1; Wnt, Wingless/Integrated; MAPK, Mitogen-activated protein kinase; MET, Mesenchymal-epithelial transition factor NA, Not available.
Summary of non-coding RNAs in EVs involved in GC progression and metastasis.
| Non-coding RNAs | Recipient cells/Target | Role/Mechanism |
|---|---|---|
| miR-155-5p | TP53INP1 mRNA | Proliferation and Migration ( |
| miR-21-5p | PMCs | Peritoneal metastasis ( |
| miR-23a | HUVECs/PTEN | Angiogenesis ( |
| lncRNA PCGEM1 | NA | Invasion and Metastasis ( |
| miR-106a | Smad7 | Peritoneal metastasis ( |
| miR-15b-3p | DYNLT1/Caspase-3/Caspase-9 Signaling Pathway | Tumorigenesis and Malignant transformation ( |
| miR-155 | Endothelial Cells/c-MYB/VEGF Axis | Angiogenesis ( |
| miR-155 | Endothelial Cells/Forkhead Box O3 | Angiogenesis ( |
| miR-196a-1 | SFRP1 | Invasion and Metastasis ( |
| miR-1290 | NKD1 | Proliferation and Invasion ( |
| miR-135b | Endothelial Cells/FOXO1 Expression | Angiogenesis ( |
| miR-501 | BLID | Chemoresistance and Tumorigenesis ( |
| miRNA expression profiles analysis: 29 miRNA were identified | NA | Peritoneal dissemination ( |
| miR-423-5p | SUFU | Cancer growth and Metastasis ( |
| miR-130a | Vascular endothelial Cells/Targeting C-MYB | Angiogenesis ( |
| miR-27a | Fibroblasts/CSRP2 | Proliferation, Motility, and Metastasis ( |
| lncRNA | NA | Progression ( |
| miR-217 | CDH1 | Carcinogenesis ( |
| Let-7 microRNA | RAS and HMGA2 | Tumorigenesis and Metastasis ( |
| miR-21 and miR-1225-5p | NA | Invasion ( |
| circNRIP1 | AKT1/mTOR pathway | Progression ( |
| circ-RanGAP1 | miR-877-3p | Invasion and Metastasis ( |
BLID, BH3-like motif-containing protein; CDH1, Cadherin-1; Evs, Extracellular vesicles; GC, Gastric cancer; HUVECs, Human umbilical vein endothelial cells; HMGA2, high mobility group AT-hook 2; mTOR, Mammalian target of rapamycin; NA, Not available; PMCs, Peritoneal mesothelial cells; PTEN, Phosphatase and tensin homolog; SUFU, Suppressor of fused protein; SFRP1, Secreted frizzled-related protein 1; VEGF, vascular endothelial growth factor.
Figure 2GC-derived EVs acts on target cells to mediate the formation of pre-metastasis niche. (A) GC-derived EVs modulate the immune microenvironment by inducing Jurkat T cells apoptosis, neutrophils autophagy, Th17 cells differentiation, functional expression of macrophages and mesenchymal stem cells, eventually promoting tumor progression and metastasis. (B) GC-derived EVs target c-MYB on vascular endothelial cells and regulate vascular stimulating factors to promote angiogenesis. (C) GC-derived EVs convert fibroblasts, pericytes, mesenchymal stem cells, PMCs to CAFs through different mechanisms. (D) Phenotypic changes and apoptosis of PMCs induced by GC-derived EVs clear the peritoneal mesothelial cell barrier layers.